GSK Glaxosmithkline plc - ADR

$GSK 👀 Really like the structure developing on the 6M chart. GSK recently broke above a multi-year descending trendline and now appears to be coming back for a potential bullish pennant breakout retest around the $50 area. If this former resistance continues to hold as support, I’ll be watching for the next higher-low and continuation move. This is a long-term swing setup, so patience is key. 📈

$GSK GSK Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer "today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway."

A rectal cancer treatment with no surgery, radiation or chemo just got FDA approval. $GSK Jemperli (MSI-H/dMMR, stage II/III): 71% of 154 patients needed no other treatment. Approved about 4 months early. Full data at ESMO Sun Oct 25. It's on the calendar 📅

$GSK Follow-up: UK drugmaker GSK (early Ris-Rez lung data, 18 Oct) won US accelerated approval for Jemperli in MSI-H/dMMR rectal cancer; on the trial's primary endpoint, independent review, 47% (54/116) had a 12-month complete response vs 68% by investigators. Niche vs a ~$106.86B market value ($49.525, 13:16 ET Oct 19, 2026): the biomarker is in about 5-10% of rectal cancers. No recurrence reported among responders after over two years' median follow-up, and 38 more short of 12 months already show complete response. Full data at ESMO this month.

$GSK What is going on here? Sold all minutes into open this morning. Ideas? Unexpected. GSK had been decent stock.

$GSK Wolfe started coverage Friday with an Outperform and a 70 target, about 50% above where the shares closed. Consensus is still a Hold at 55.33, so Wolfe is roughly 27% above the street on a name down 20% over the last six months. Initiating that high on a beaten-up pharma stock is a pretty loud call.

The research continues and the AI overlords have been assigned another FDA decision to predict. Let's see how close it can get to it's predictions. $GSK — PDUFA: Oct. 26 Bepirovirsen for chronic hepatitis B. Priority Review + Breakthrough Therapy, backed by Phase 3 B-Well 1 & 2 where functional cure hit 19% vs. 0% with SoC alone. AI model call: • Approval probability: 95% • Estimated move on approval: +1.3% • Estimated move on miss: -1.7%

$GSK Excellent entry point. Strong support at 48.98. Worth $65 and they do have some mRNA expertise. Don't expect Moderna like action but up and to the right. Nice steady gainer for the future.